Literature DB >> 11897640

Mutations of the cystic fibrosis gene and intermediate sweat chloride levels in children.

Patrick Lebecque1, Teresinha Leal, Christiane De Boeck, Martine Jaspers, Harry Cuppens, Jean-Jacques Cassiman.   

Abstract

The incidence of mutations of the cystic fibrosis transmembrane conductance regulator (CFTR) gene in children with intermediate sweat chloride levels is unknown. The results of 2,349 sweat tests performed at two Belgian university hospitals were reviewed. Intermediate chloride concentrations were observed in 98 subjects (4.2%), 68 being younger than 18 years of age. Forty-three children could be traced and their parents agreed to take part in the study. Exhaustive analysis of the CFTR gene disclosed a total of 24 putative mutations (27.9%). Three subjects were found to carry only one CFTR mutation, whereas 10 harbored one mutation on both CFTR genes. These 10 children were investigated in detail. At the time of writing, the mean age (+/-SD) of this group is 8.9 years (+/-4.2 years). Nine children are pancreatic sufficient. Three have been asymptomatic for more than two years, whereas the others display, to different degrees, clinical features suggestive of CF. The sweat chloride concentration is slightly higher in this group (39.4 +/- 5.4 mM) than in subjects without CFTR mutation (35.2 +/- 4.4 mM, p < 0.05). The nasal potential difference was abnormal in five of the nine subjects tested. In this study, 23% of children displaying intermediate sweat chloride levels were found to carry a putative mutation on both CFTR genes.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11897640     DOI: 10.1164/ajrccm.165.6.2104073

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  8 in total

1.  Sweat testing in CF.

Authors:  Lutz Naehrlich
Journal:  Thorax       Date:  2007-05       Impact factor: 9.139

2.  Sweat chloride levels in asthma.

Authors:  Anirban Mandal; S K Kabra
Journal:  Indian J Pediatr       Date:  2014-12-28       Impact factor: 1.967

3.  Proof of concept for identifying cystic fibrosis from perspiration samples.

Authors:  Zhenpeng Zhou; Daniel Alvarez; Carlos Milla; Richard N Zare
Journal:  Proc Natl Acad Sci U S A       Date:  2019-11-18       Impact factor: 11.205

4.  Factors accounting for a missed diagnosis of cystic fibrosis after newborn screening.

Authors:  Michael J Rock; Hara Levy; Christina Zaleski; Philip M Farrell
Journal:  Pediatr Pulmonol       Date:  2011-08-24

Review 5.  Cystic fibrosis: terminology and diagnostic algorithms.

Authors:  K De Boeck; M Wilschanski; C Castellani; C Taylor; H Cuppens; J Dodge; M Sinaasappel
Journal:  Thorax       Date:  2005-12-29       Impact factor: 9.139

Review 6.  Cystic fibrosis.

Authors:  Felix Ratjen; Scott C Bell; Steven M Rowe; Christopher H Goss; Alexandra L Quittner; Andrew Bush
Journal:  Nat Rev Dis Primers       Date:  2015-05-14       Impact factor: 52.329

7.  Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation consensus report.

Authors:  Philip M Farrell; Beryl J Rosenstein; Terry B White; Frank J Accurso; Carlo Castellani; Garry R Cutting; Peter R Durie; Vicky A Legrys; John Massie; Richard B Parad; Michael J Rock; Preston W Campbell
Journal:  J Pediatr       Date:  2008-08       Impact factor: 4.406

8.  Sweat chloride as a biomarker of CFTR activity: proof of concept and ivacaftor clinical trial data.

Authors:  Frank J Accurso; Fredrick Van Goor; Jiuhong Zha; Anne J Stone; Qunming Dong; Claudia L Ordonez; Steven M Rowe; John Paul Clancy; Michael W Konstan; Heather E Hoch; Sonya L Heltshe; Bonnie W Ramsey; Preston W Campbell; Melissa A Ashlock
Journal:  J Cyst Fibros       Date:  2014-03       Impact factor: 5.527

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.